There are three parts to this Phase 1/2 study in subjects with advanced melanoma:~Phase 1a will identify the MTD and preliminary safety of combination hydroxychloroquine and nivolumab therapy.~Phase 1b will identify the MTD and preliminary safety of hydroxychloroquine administered in conjunction with nivolumab and ipilimumab therapy~Phase 2 will assess the clinical efficacy of combination hydroxychloroquine and nivolumab therapy.
This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.